Show simple item record

dc.contributor.authorKhan, S
dc.contributor.authorKhanal, S
dc.contributor.authorAouira, N
dc.contributor.authorScuffham, P
dc.contributor.authorBor, W
dc.contributor.authorHeussler, H
dc.contributor.authorMcDermott, B
dc.contributor.authorHaywood, A
dc.contributor.authorDown, J
dc.contributor.authorLittlewood, R
dc.date.accessioned2020-07-06T03:47:58Z
dc.date.available2020-07-06T03:47:58Z
dc.date.issued2018
dc.identifier.issn1098-3015
dc.identifier.doi10.1016/j.jval.2018.09.1641
dc.identifier.urihttp://hdl.handle.net/10072/395177
dc.description.abstractObjectives: Global risk of atypical antipsychotics (ATPs) induced metabolic syndrome (MS) is high with increasing prescription rates. Metabolic monitoring systems reduces the burden of MS, however, is poorly performed in clinical setting. The objective of this study was to critically assesses the cost implications of ATPs induced MS and metabolic monitoring. Methods: Primary studies on cost analysis of ATPs induced MS were assessed based on consolidated health economic evaluation reporting standards (CHEERS). Inclusion criteria were: cost analysis of ATPs induced MS and cost of metabolic monitoring of ATPs vs. no ATPs/MS, published from 2000-April 2018. Economic models expressed in cost per quality-adjusted life year (QALY) were analysed. MEDLINE, EMBASE, CENTRAL databases and cost-effectiveness analysis registry were searched. Primary outcomes were (i) Reporting standards; (ii) Technical merits and (iii) applicability to local decision making with diverse perspectives. Results: Three studies were included which modelled 16,371 cohorts (including a simulated hypothetical cohort of 10,000 patients) from healthcare provider, payer and societal perspectives. One study complied with the CHEERS statement whereas the other two demonstrated partial pharmacoeconomics evaluation. ATPs induced MS incurred significantly higher total care costs compared with those without these conditions (F=710.08; p<0.0001) or those not treated with ATPs (F=2855.54; p<0.0001). Burden of MS was higher among youth. Ziprasidone appeared cost effective as compared to olanzapine and quetiapine in the management of schizophrenia. Ziprasidone also led to marginally higher QALYs when compared with risperidone, however, was costlier (each QALY gained costs an additional $218 060). None of the studies assessed the cost effectiveness of metabolic monitoring systems. Conclusions: ATPs induced MS is associated with significantly higher healthcare services costs. Burden of illness is higher among youth as compared to adults. Risperidone and Ziprasidone appears cost effective with QALY gained. Lack of cost effectiveness studies of metabolic monitoring systems demonstrates technical inefficiency.
dc.languageEnglish
dc.publisherElsevier
dc.relation.ispartofconferencenameMoving Into Action: Informing Policy and Strengthening Healthcare Systems in Asia Pacific
dc.relation.ispartofconferencetitleVALUE IN HEALTH
dc.relation.ispartofdatefrom2018-09-08
dc.relation.ispartofdateto2018-09-11
dc.relation.ispartoflocationTokyo, Japan
dc.relation.ispartofpagefromS276
dc.relation.ispartofpagefrom1 pages
dc.relation.ispartofpagetoS276
dc.relation.ispartofpageto1 pages
dc.relation.ispartofissueSupplement 2
dc.relation.ispartofvolume21
dc.subject.fieldofresearchApplied economics
dc.subject.fieldofresearchHealth services and systems
dc.subject.fieldofresearchPolicy and administration
dc.subject.fieldofresearchcode3801
dc.subject.fieldofresearchcode4203
dc.subject.fieldofresearchcode4407
dc.subject.keywordsSocial Sciences
dc.subject.keywordsScience & Technology
dc.subject.keywordsLife Sciences & Biomedicine
dc.subject.keywordsEconomics
dc.subject.keywordsHealth Care Sciences & Services
dc.titlePharmacoeconomics of atypical antipsychotics induced metabolic syndrome: A critical evaluation of cost implications and health outcomes
dc.typeConference output
dc.type.descriptionE3 - Conferences (Extract Paper)
dcterms.bibliographicCitationKhan, S; Khanal, S; Aouira, N; Scuffham, P; Bor, W; Heussler, H; McDermott, B; Haywood, A; Down, J; Littlewood, R, Pharmacoeconomics of atypical antipsychotics induced metabolic syndrome: A critical evaluation of cost implications and health outcomes, Value in Health, 2018, 21, pp. S276-S276
dc.date.updated2020-07-06T03:43:23Z
gro.hasfulltextNo Full Text
gro.griffith.authorHaywood, Alison
gro.griffith.authorScuffham, Paul A.
gro.griffith.authorKhan, Sohil A.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Conference outputs
    Contains papers delivered by Griffith authors at national and international conferences.

Show simple item record